TomTom delivers highly automated driving maps for all interstate roads in California & Michigan
TomTom (TOM2) today announces the launch of its Highly Automated Driving (HAD) map products for all interstate roads in California and all interstates and freeways in Michigan. By delivering TomTom’s HAD Map and RoadDNA products for states that serve as testing grounds for driverless cars, TomTom is enabling the automotive industry to bring autonomous driving closer to reality.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160105006393/en/
“I am proud of TomTom’s extended HAD leadership demonstrated by delivering 25,000 kilometers of HAD maps for the United States, less than four months following the launch of our HAD Map for the Autobahn network in Germany ,” said Harold Goddijn, CEO at TomTom. “TomTom is more excited than ever about the prospect of partnering with members of the HAD ecosystem to expedite the innovation that will transform the automotive industry and the way we drive.”
TomTom’s HAD Map delivers a highly accurate and realistic 3D border-to-border model of the road and TomTom RoadDNA delivers a pattern based localization solution. By matching TomTom RoadDNA data with vehicle sensor data and the HAD Map in real time, a vehicle knows its precise position, even while traveling at high speeds or when changes occur to the roadside.
Check out TomTom’s HAD map products in a car cockpit demo at CES: Booth 73904 at the Sands Expo.
Notes to editors:
- The TomTom HAD Map covers all net2class 0 roads in California (12,000 kilometers) and all net2class 0 and 1 in Michigan (13,000 kilometers)
- Net2class 0 = interstates
- Net2class 1 = freeways and highways
- The TomTom HAD Map for California & Michigan is available in XML and Shapefile format
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can benefit from it.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We have four customer facing business units: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,400 employees worldwide and sell our products in 48 countries.
+31 (0)6 252 991 52
Head of Treasury and Investor Relations
+31 20 75 75 194
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum